Multiple well-established therapies are available to treat Crohn’s disease (CD). In particular, the most widely used biologics—the TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira)—have helped advance CD treatment, especially for moderate to severe disease, and are now entrenched as first-line biologics. In the past three years, the CD treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), one stemcell therapy (i.e., TiGenix/Takeda’s Alofisel), and the launch of several biosimilars of infliximab and adalimumab (e.g., Celltrion’s Remsima, Amgen’s Amgevita), further expanding physicians’ treatment armamentarium. Indeed, the availability of these agents has influenced physicians’ prescribing behavior and will continue to have an impact on the treatment landscape.
Questions Answered:
Markets covered: France, Germany, Italy, Spain, and United Kingdom
Primary research: 251 gastroenterologists completed the survey. Of that total, 50 respondents were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 51 in the United Kingdom. The survey was fielded from July 22 to August 16, 2019.
Key companies: Merck & Co., Celltrion, Hospira, Biogen, AbbVie/Eisai, Biogen, Amgen, Sandoz, Takeda, Janssen, others
Key drugs: adalimumab (Humira and biosimilars), Entyvio, infliximab (Remicade and biosimilars), Stelara
Product Description: Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.